Role of glial cell line-derived neurotrophic factor in perineural invasion of pancreatic cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1826, Issue 1, 2012, Pages 112-120

  Liu, Han ^a   Li, Xuqi ^a   Xu, Qinhong ^a   Lv, Shifang ^a   Li, Junhui ^a,b   Ma, Qingyong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Neuro cancer interaction; Neurotrophic factor; Pancreatic cancer; Perineural invasion; RET; Targeted therapy

Indexed keywords

4 AMINOPYRAZOLO[3,4 D]PYRIMIDINE; ARYLIDENE 2 INDOLINONE; GELATINASE B; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE; OXINDOLE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN RET; PYRAZOLOPYRIMIDINE DERIVATIVE; RAS PROTEIN; RPI 1; SEMAXANIB; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER INFILTRATION; CANCER INVASION; CANCER RECURRENCE; CELL PROLIFERATION; CHEMOTAXIS; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; METASTASIS POTENTIAL; MOLECULAR MECHANICS; NERVE PLEXUS; PANCREAS CANCER; PERINEURAL INVASION; PERINEURIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETROPERITONEAL NERVE PLEXUS; REVIEW; SIGNAL TRANSDUCTION;

GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTORS; HUMANS; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PERIPHERAL NERVOUS SYSTEM NEOPLASMS;

EID: 84860215595     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.03.010     Document Type: Review

References (74)

1. Shaib Y.H., Davila J.A., El-Serag H.B. The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment. Pharmacol. Ther. 2006, 24:87-94.
2. Siegel R., Naishadham D., Jemal A. Cancer Statistics, 2012. CA Cancer J. Clin. 2012, 62:10-29.
3. Cartwright T., Richards D.A., Boehm K.A. Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network. Cancer Control 2008, 15:308-313.
4. Chakraborty S., Baine M.J., Sasson A.R., Batra S.K. Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim. Biophys. Acta-Rev. Cancer 2011, 1815:44-64.
5. Kayahara M., Nagakawa T., Konishi I., Ueno K., Ohta T., Miyazaki I. Clinicopathological study of pancreatic-carcinoma with particular reference to the invasion of the extrapancreatic neural plexus. Int. J. Pancreatol. 1991, 10:105-111.
6. Pour P.M., Bell R.H., Batra S.K. Neural invasion in the staging of pancreatic cancer. Pancreas 2003, 26:322-325.
7. Hibi T., Mori T., Fukuma M., Yamazaki K., Hashiguchi A., Yamada T., Tanabe M., Aiura K., Kawakami T., Ogiwara A., Kosuge T., Kitajima M., Kitagawa Y., Sakamoto M. Synuclein-gamma is closely involved in perineural invasion and distant metastasis in mouse models and is a novel prognostic factor in pancreatic cancer. Clin. Cancer Res. 2009, 15:2864-2871.
8. Ceyhan G.O., Bergmann F., Kadihasanoglu M., Altintas B., Demir I.E., Hinz U., Mueller M.W., Giese T., Buechler M.W., Giese N.A., Friess H. Pancreatic neuropathy and neuropathic pain-a comprehensive pathomorphological study of 546 cases. Gastroenterology 2009, 136:177-186.
9. Okusaka T., Okada S., Ueno H., Ikeda M., Shimada K., Yamamoto J., Kosuge T., Yamasaki S., Fukushima N., Sakamoto M. Abdominal pain in patients with resectable pancreatic cancer with reference to clinicopathologic findings. Pancreas 2001, 22:279-284.
10. Ceyhan G.O., Michalski C.W., Demir I.E., Muller M.W., Friess H. Pancreatic pain. Best Pract. Res. Clin. Gastroenterol. 2008, 22:31-44.
11. Bapat A.A., Hostetter G., Von Hoff D.D., Han H. Perineural invasion and associated pain in pancreatic cancer. Nat. Rev. Cancer 2011, 11:695-707.
12. Deshmukh S.D., Willmann J.K., Jeffrey R.B. Pathways of extrapancreatic perineural invasion by pancreatic adenocarcinoma: evaluation with 3D volume-rendered MDCT imaging. Am. J. Roentgenol. 2010, 194:668-674.
13. Liebig C., Ayala G., Wilks J.A., Berger D.H., Albo D. Perineural invasion in cancer: a review of the literature. Cancer 2009, 115:3379-3391.
14. Abiatari I., DeOliveira T., Kerkadze V., Schwager C., Esposito I., Giese N.A., Huber P., Bergman F., Abdollahi A., Friess H., Kleeff J. Consensus transcriptome signature of perineural invasion in pancreatic carcinoma. Mol. Cancer Ther. 2009, 8:1494-1504.
15. Nagakawa T., Mori K., Nakano T., Kadoya M., Kobayashi H., Akiyama T., Kayahara M., Ohta T., Ueno K., Higashino Y., Konishi I., Miyazaki I. Perineural invasion of carcinoma of the pancreas and biliary-tract. Br. J. Surg. 1993, 80:619-621.
16. Hirai I., Kimura W., Ozawa K., Kudo S., Suto K., Kuzu H., Fuse A. Perineural invasion in pancreatic cancer. Pancreas 2002, 24:15-25.
17. Ochiai A., Mitsunaga S., Hasebe T., Kinoshita T., Konishi M., Takahashi S., Gotohda N., Nakagohri T. Detail histologic analysis of nerve plexus invasion in invasive ductal carcinoma of the pancreas and its prognostic impact. Am. J. Surg. Pathol. 2007, 31:1636-1644.
18. Dunn M., Morgan M.B., Beer T.W. Perineural invasion: identification, significance, and a standardized definition. Dermatol. Surg. 2009, 35:214-221.
19. Liu B., Lu K.Y. Neural invasion in pancreatic carcinoma. Hepatobiliary Pancreat. Dis. Int. 2002, 1:469-476.
20. Nagakawa T., Kayahara M., Ueno K., Ohta T., Konishi I., Miyazaki I. Clinicopathological study on neural invasion to the extrapancreatic nerve plexus in pancreatic cancer. Hepatogastroenterology 1992, 39:51-55.
21. Kayahara M., Nakagawara H., Kitagawa H., Ohta T. The nature of neural invasion by pancreatic cancer. Pancreas 2007, 35:218-223.
22. Nagakawa T., Kayahara M., Ohta T., Ueno K., Konishi I., Miyazaki I. Patterns of neural and plexus invasion of human pancreatic-cancer and experimental cancer. Int. J. Pancreatol. 1991, 10:113-119.
23. Marchesi F., Piemonti L., Mantovani A., Allavena P. Molecular mechanisms of perineural invasion, a forgotten pathway of dissemination and metastasis. Cytokine Growth Factor Rev. 2010, 21:77-82.
24. Ceyhan G.O., Schafer K.H., Kerscher A.G., Rauch U., Demir I.E., Kadihasanoglu M., Bohm C., Muller M.W., Buchler M.W., Giese N.A., Erkan M., Friess H. Nerve growth factor and artemin are paracrine mediators of pancreatic neuropathy in pancreatic adenocarcinoma. Ann. Surg. 2010, 251:923-931.
25. Zhu Z.W., Friess H., Wang L., Bogardus T., Korc R., Kleeff J., Buchler M.W. Nerve growth factor exerts differential effects on the growth of human pancreatic cancer cells. Clin. Cancer Res. 2001, 7:105-112.
26. Okada Y., Eibl G., Guha S., Duffy J.P., Reber H.A., Hines O.J. Nerve growth factor stimulates MMP-2 expression and activity and increases invasion by human pancreatic cancer cells. Clin. Exp. Metastasis 2004, 21:285-292.
27. Ketterer K., Rao S., Friess H., Weiss J., Buchler M.W., Korc M. Reverse transcription-PCR analysis of laser-captured cells points to potential paracrine and autocrine actions of neurotrophins in pancreatic cancer. Clin. Cancer Res. 2003, 9:5127-5136.
28. Gil Z., Cavel O., Kelly K., Brader P., Rein A., Gao S.P., Carlson D.L., Shah J.P., Fong Y., Wong R.J. Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves. J. Natl. Cancer Inst. 2010, 102:107-118.
29. Ceyhan G.O., Giese N.A., Erkan M., Kerscher A.G., Wente M.N., Giese T., Buchler M.W., Friess H. The neurotrophic factor artemin promotes pancreatic cancer invasion. Ann. Surg. 2006, 244:274-281.
30. Okada Y., Takeyama H., Sato M., Morikawa M., Sobue K., Asai K., Tada T., Kato T., Manabe T. Experimental implication of celiac ganglionotropic invasion of pancreatic-cancer cells bearing c-ret proto-oncogene with reference to glial-cell-line-derived neurotrophic factor (GDNF). Int. J. Cancer 1999, 81:67-73.
31. Zeng Q., Cheng Y., Zhu Q., Yu Z., Wu X., Huang K., Zhou M., Han S., Zhang Q. The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer. J. Int. Med. Res. 2008, 36:656-664.
32. Ito Y., Okada Y., Sato M., Sawai H., Funahashi H., Murase T., Hayakawa T., Manabe T. Expression of glial cell line-derived neurotrophic factor family members and their receptors in pancreatic cancers. Surgery 2005, 138:788-794.
33. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260:1130-1132.
34. Airaksinen M.S., Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. 2002, 3:383-394.
35. Durbec P., MarcosGutierrez C.V., Kilkenny C., Grigoriou M., Wartiovaara K., Suvanto P., Smith D., Ponder B., Costantini F., Saarma M., Sariola H., Pachnis V. GDNF signalling through the Ret receptor tyrosine kinase. Nature 1996, 381:789-793.
36. Castellone M.D., Santoro M. Dysregulated RET signaling in thyroid cancer. Endocrinol. Metab. Clin. 2008, 37:363-374.
37. Hansford J.R., Mulligan L.M. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J. Med. Genet. 2000, 37:817-827.
38. Sawai H., Okada Y., Kazanjian K., Kim J., Hasan S., Hines O.J., Reber H.A., Hoon D.S.B., Eibl G. The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. Cancer Res. 2005, 65:11536-11544.
39. Ceyhan G.O., Demir I.E., Altintas B., Rauch U., Thiel G., Muller M.W., Giese N.A., Friess H., Schafer K.H. Neural invasion in pancreatic cancer: a mutual tropism between neurons and cancer cells. Biochem. Biophys. Res. Commun. 2008, 374:442-447.
40. Liu H., Ma Q.Y., Li J.H. High glucose promotes cell proliferation and enhances GDNF and RET expression in pancreatic cancer cells. Mol. Cell. Biochem. 2011, 347:95-101.
41. Ben Q.W., Wang J.C., Liu J., Zhu Y., Yuan F., Yao W.Y., Yuan Y.Z. Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma. Ann. Surg. Oncol. 2010, 17:2213-2221.
42. Funahashi H., Takeyama H., Sawai H., Furuta A., Sato M., Okada Y., Hayakawa T., Tanaka M., Manabe T. Alteration of integrin expression by glial cell line-derived neurotrophic factor (GDNF) in human pancreatic cancer cells. Pancreas 2003, 27:190-196.
43. Funahashi H., Okada Y., Sawai H., Takahashi H., Matsuo Y., Takeyama H., Manabe T. The role of glial cell line-derived neurotrophic factor (GDNF) and integrins for invasion and metastasis in human pancreatic cancer cells. J. Surg. Oncol. 2005, 91:77-83.
44. Veit C., Genze F., Menke A., Hoeffert S., Gress T.M., Gierschik P., Giehl K. Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells. Cancer Res. 2004, 64:5291-5300.
45. Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev. 2001, 12:361-373.
46. Okada Y., Eibl G., Duffy J.P., Reber H.A., Hines O.J. Glial cell-derived neurotrophic factor upregulates the expression and activation of matrix metalloproteinase-9 in human pancreatic cancer. Surgery 2003, 134:293-299.
47. Grzesiak J.J., Bouvet M. Divalent cations modulate the integrin-mediated malignant phenotype in pancreatic cancer cells. Cancer Sci. 2008, 99:1553-1563.
48. Wang Z., Li Y., Ahmad A., Banerjee S., Azmi A.S., Kong D., Sarkar F.H. Pancreatic cancer: understanding and overcoming chemoresistance. Nat. Rev. Gastroenterol. Hepatol. 2011, 8:27-33.
49. Yang X.Q., Staren E.D., Howard J.M., Iwamura T., Bartsch J.E., Appert H.E. Invasiveness and MMP expression in pancreatic carcinoma. J. Surg. Res. 2001, 98:33-39.
50. Mroczko B., Lukaszewicz-Zajac M., Wereszczynska-Siemiatkowska U., Groblewska M., Gryko M., Kedra B., Jurkowska G., Szmitkowski M. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer metalloproteinase-9 as an independent prognostic factor. Pancreas 2009, 38:613-618.
51. Lu Z.X., Li Y., Takwi A., Li B.H., Zhang J.W., Conklin D.J., Young K.H., Martin R., Li Y. miR-301a as an NF-kappa B activator in pancreatic cancer cells. EMBO J. 2011, 30:57-67.
52. Asano T., Yao Y.X., Zhu J.J., Li D.H., Abbruzzese J.L., Reddy S.A.G. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappa B and c-Myc in pancreatic cancer cells. Oncogene 2004, 23:8571-8580.
53. Zhang D., Ma Q.Y., Hu H.T., Zhang M. beta(2)-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NF kappa B and AP-1. Cancer Biol. Ther. 2010, 10:19-29.
54. Takahashi H., Funahashi H., Sawai H., Sakamoto M., Matsuo Y., Yamamoto M., Okada Y., Hayakawa T., Manabe T. Glial cell line-derived neurotrophic factor enhances nuclear factor-kappa B activity and invasive potential in human pancreatic cancer cells. Pancreas 2004, 29:22-27.
55. Lanzi C., Cassinelli G., Cuccuru G., Zaffaroni N., Supino R., Vignati S., Zanchi C., Yamamoto M., Zunino F. Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Cell. Mol. Life Sci. 2003, 60:1449-1459.
56. Krause D.S., Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 2005, 353:172-187.
57. Carlomagno F., Anaganti S., Guida T., Salvatore G., Troncone G., Wilhelm S.M., Santoro M. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl. Cancer Inst. 2006, 98:326-334.
58. Phay J.E., Shah M.H. Targeting RET receptor tyrosine kinase activation in cancer. Clin. Cancer Res. 2010, 16:5936-5941.
59. Motzer R.J., Hoosen S., Bello C.L., Christensen J.G. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin. Investig. Drugs 2006, 15:553-561.
60. Carlomagno F., Vitagliano D., Guida T., Ciardiello F., Tortora G., Vecchio G., Ryan A.J., Fontanini G., Fusco A., Santor M. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002, 62:7284-7290.
61. Kosmider O., Denis N., Dubreuil P., Moreau-Gachelin F. Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate. Oncogene 2007, 26:3904-3908.
62. O'Farrell A.M., Yuen H.A., Smolich B., Hannah A.L., Louie S.G., Hong W.R., Stopeck A.T., Silverman L.R., Lancet J.E., Karp J.E., Albitar M., Cherrington J.M., Giles F.J. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk. Res. 2004, 28:679-689.
63. Mologni L., Sala E., Cazzaniga S., Rostagno R., Kuoni T., Puttini M., Bain J., Cleris L., Redaelli S., Riva B., Formelli F., Scapozza L., Gambacorti-Passerini C. Inhibition of RET tyrosine kinase by SU5416. J. Mol. Endocrinol. 2006, 37:199-212.
64. Wang S.Y., Chen B., Zhan Y.Q., Xu W.X., Li C.Y., Yang R.F., Zheng H., Yue P.B., Larsen S.H., Sun H.B., Yang X.M. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. J. Hepatol. 2004, 41:267-273.
65. Cuccuru G., Lanzi C., Cassinelli G., Pratesi G., Tortoreto M., Petrangolini G., Seregni E., Martinetti A., Laccabue D., Zanchi C., Zunino F. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J. Natl. Cancer Inst. 2004, 96:1006-1014.
66. Caccia D., Micciche F., Cassinelli G., Mondellini P., Casalini P., Bongarzone I. Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line. Mol. Cancer 2010, 9.
67. Rashad A.E., Mahmoud A.E., Ali M.M. Synthesis and anticancer effects of some novel pyrazolo[3,4-d]pyrimidine derivatives by generating reactive oxygen species in human breast adenocarcinoma cells. Eur. J. Med. Chem. 2011, 46:1019-1026.
68. Carraro F., Naldini A., Pucci A., Locatelli G.A., Maga G., Schenone S., Bruno O., Ranise A., Bondavalli F., Brullo C., Fossa P., Menozzi G., Mosti L., Modugno M., Tintori C., Manetti F., Botta M. Pyrazolo 3,4-d pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation. J. Med. Chem. 2006, 49:1549-1561.
69. Hirokawa Y., Levitzki A., Lessene G., Baell J., Xiao Y., Zhu H., Maruta H. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors). Cancer Lett. 2007, 245:242-251.
70. Ito H., Gardner-Thorpe J., Zinner M.J., Ashley S.W., Whang E.E. Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery 2003, 134:221-226.
71. Menke A., Philippi C., Vogelmann R., Seidel B., Lutz M.P., Adler G., Wedlich D. Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines. Cancer Res. 2001, 61:3508-3517.
72. Ungefroren H., Sebens S., Groth S., Gieseler F., Fandrich F. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors. Curr. Cancer Drug Targets 2011, 11:524-535.
73. Antonelli A., Bocci G., La Motta C., Ferrari S.M., Fallahi P., Fioravanti A., Sartini S., Minuto M., Piaggi S., Corti A., Ali G., Berti P., Fontanini G., Danesi R., Da Settimo F., Miccoli P. Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J. Clin. Endocrinol. Metab. 2011, 96:E288-E296.
74. Bocci G., Fioravanti A., La Motta C., Orlandi P., Canu B., Di Desidero T., Mugnaini L., Sartini S., Cosconati S., Frati R., Antonelli A., Berti P., Miccoli P., Da Settimo F., Danesi R. Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells. Biochem. Pharmacol. 2011, 81:1309-1316.